News

US FDA extends review of GSK's blood cancer drug
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.
GSK blood cancer drug reapproved by EU regulator
GSK’s blood cancer drug Blenrep has been reapproved by the EU medicines regulator after it was removed from sale in 2023 because a trial failed to show it was superior to other treatments.
GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning
Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) combinations. The belantamab mafodotin combinations were evaluated in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
GSK wins EU approval for drug combos containing blood cancer drug Blenrep
GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple myeloma. Read more here.
GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data
FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.
GSK's blood cancer drug fails to secure US FDA advisers' support
The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns about previously documented risks of eye-related side effects, sending the British drugmaker's U.
GSK's blood cancer drug gets EU approval
The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood plasma cells, the British drugmaker said on Thursday. EU regulators approved Blenrep after phase III trials showed the drug,
BioSpace7h

GSK Bets Up To $12B for Multi-Program Cancer Pact With Hengrui

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...
BioPharma Dive9h

GSK pays $500M to enter drugmaking alliance with Hengrui

The deal, which will focus first on a COPD therapy GSK believes holds “best-in-class” potential, could ultimately involve a ...
STAT10d

FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...
Logically Answered on MSN18d

Why 77,000 cancer patients are suing pfizer & others

The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic nightmare linked to cancer and massive lawsuits? In this video, we uncover the ...